Literature DB >> 10982293

Fludarabine-based conditioning for allogeneic transplantation in adults with sickle cell disease.

K van Besien1, A Bartholomew, W Stock, D Peace, S Devine, D Sher, J Sosman, Y H Chen, M Koshy, R Hoffman.   

Abstract

Although allogeneic transplantation can be curative for patients with sickle cell disease, the toxicity of conditioning regimens has precluded its use in adults with significant end-organ damage. Newer conditioning regimens have been developed that are less toxic and that may broaden the applicability of allogeneic transplantation in this disorder. We report two adults with end-stage sickle cell disease, who underwent allogeneic transplantation from an HLA-identical sibling donor after conditioning with fludarabine/melphalan and ATG. Both patients had been extensively transfused and one had multiple RBC antibodies. One of the patients also had end-stage renal disease, and was dialysis dependent. Engraftment occurred promptly in both patients. Both achieved 100% donor chimerism and both were free of pain crises after transplant. The first patient died of a respiratory failure related to chronic graft-versus-host disease (GVHD) on day 335 after transplantation. The second patient developed severe gastro-intestinal GVHD and TTP and died on day 147 after transplantation. Conditioning with fludarabine/melphalan and ATG followed by allogeneic stem cell transplantation resulted in prompt and reliable engraftment in adults with end-stage sickle cell disease. The incidence of severe GVHD was unacceptably high and may be related to the ethnicity of the patients or to the inflammatory state associated with pre-existing sickle cell disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10982293     DOI: 10.1038/sj.bmt.1702518

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  19 in total

1.  Challenges and opportunities for international cooperative studies in pediatric hematopoeitic cell transplantation: priorities of the Westhafen Intercontinental Group.

Authors:  Rudolph Kirk R Schultz; Kevin Scott Baker; Jaap J Boelens; Catherine M Bollard; R Maarten Egeler; Mort Cowan; Ruth Ladenstein; Arjan Lankester; Franco Locatelli; Anita Lawitschka; John E Levine; Mignon Loh; Eneida Nemecek; Charlotte Niemeyer; Vinod K Prasad; Vanderson Rocha; Shalini Shenoy; Brigitte Strahm; Paul Veys; Donna Wall; Peter Bader; Stephan A Grupp; Michael A Pulsipher; Christina Peters
Journal:  Biol Blood Marrow Transplant       Date:  2013-07-21       Impact factor: 5.742

Review 2.  Hematopoietic stem cell transplantation for people with ß-thalassaemia major.

Authors:  Vanitha A Jagannath; Zbys Fedorowicz; Amani Al Hajeri; Akshay Sharma
Journal:  Cochrane Database Syst Rev       Date:  2016-11-30

3.  The role of donor-derived veto cells in nonmyeloablative haploidentical HSCT.

Authors:  N Or-Geva; Y Reisner
Journal:  Bone Marrow Transplant       Date:  2015-06       Impact factor: 5.483

4.  Cyclophosphamide improves engraftment in patients with SCD and severe organ damage who undergo haploidentical PBSCT.

Authors:  Courtney D Fitzhugh; Matthew M Hsieh; Tiffani Taylor; Wynona Coles; Katherine Roskom; Delon Wilson; Elizabeth Wright; Neal Jeffries; Christopher J Gamper; Jonathan Powell; Leo Luznik; John F Tisdale
Journal:  Blood Adv       Date:  2017-04-19

Review 5.  Pediatric sickle cell disease: past successes and future challenges.

Authors:  Emily Riehm Meier; Angeli Rampersad
Journal:  Pediatr Res       Date:  2016-10-05       Impact factor: 3.756

Review 6.  Hematopoietic stem cell transplantation for patients with sickle cell disease: progress and future directions.

Authors:  Courtney D Fitzhugh; Allistair A Abraham; John F Tisdale; Matthew M Hsieh
Journal:  Hematol Oncol Clin North Am       Date:  2014-09-29       Impact factor: 3.722

Review 7.  Allogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is now.

Authors:  Matthew M Hsieh; Courtney D Fitzhugh; John F Tisdale
Journal:  Blood       Date:  2011-05-31       Impact factor: 22.113

8.  Reduced intensity HLA-haploidentical BMT with post transplantation cyclophosphamide in nonmalignant hematologic diseases.

Authors:  R A Brodsky; L Luznik; J Bolaños-Meade; M S Leffell; R J Jones; E J Fuchs
Journal:  Bone Marrow Transplant       Date:  2008-07-14       Impact factor: 5.483

9.  Fludarabine-based nonmyeloablative stem cell transplantation for sickle cell disease with and without renal failure: clinical outcome and pharmacokinetics.

Authors:  Mitchell E Horwitz; Ivan Spasojevic; Ashley Morris; Marilyn Telen; James Essell; Cristina Gasparetto; Keith Sullivan; Gwynn Long; John Chute; Nelson Chao; David Rizzieri
Journal:  Biol Blood Marrow Transplant       Date:  2007-12       Impact factor: 5.742

10.  Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype.

Authors:  Matthew M Hsieh; Courtney D Fitzhugh; R Patrick Weitzel; Mary E Link; Wynona A Coles; Xiongce Zhao; Griffin P Rodgers; Jonathan D Powell; John F Tisdale
Journal:  JAMA       Date:  2014-07-02       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.